BACKGROUND: Osteoradionecrosis (ORN) of the mandible is a late toxicity affecting patients treated with radiotherapy for head and neck malignancies. To the authors' knowledge, ORN has no standardized grading system and its reporting is based on retrospective findings in heterogeneous patient populations. The rate of ORN in the era of intensity-modulated radiotherapy (IMRT) still is unknown. METHODS: The authors report the incidence of ORN from prospectively collected data regarding 1196 patients who were diagnosed with squamous cell carcinoma of the oropharynx and treated with curative-intent IMRT, with or without concomitant systemic treatment, from January 2005 to December 2014. Each case of ORN was graded according to its severity. Clinical and dosimetric comparisons were performed between patients with ORN and a matched control cohort of patients without ORN. RESULTS: The actuarial rate of ORN of the mandible was 3% at 1 year, 5% at 3 years, and 7% at 5 years. On multivariable analysis, smoking (hazard ratio, 1.9; 95% confidence interval, 1.07-3.4 [P 5.03]) and T classification (hazard ratio, 1.78; 95% confidence interval, 1.02-3.1 [P 5.041]) were found to be statistically significant risk factors. The presence of cardiovascular comorbidities, use of bisphosphonates, and pre-IMRT dental extractions were found to be different between the matched cohorts. The mandibular volume receiving 50 grays (Gy) (in cm KEYWORDS: intensity-modulated radiotherapy (IMRT), late toxicity, mandible, oropharyngeal carcinoma, osteoradionecrosis.
INTRODUCTION
Oropharyngeal carcinoma (OPC) represents the most common head and neck (HN) site of squamous cell malignancy. In the study institution, intensity-modulated radiotherapy (IMRT), specifically with or without systemic therapy, is the standard treatment of patients with OPC. IMRT improves the avoidance of normal tissues while maintaining target coverage. The impact of parotid-sparing IMRT on quality of life has been demonstrated by a randomized clinical trial. 1 Osteoradionecrosis (ORN) of the mandible is a late complication of RT to the HN, characterized by nonhealing mucosal and bone injury, occurring spontaneously or after trauma, and seriously impacting the quality of life of patients. 2 To the best of our knowledge, there currently is no consensus regarding the most appropriate grading system for ORN. The incidence of ORN at 5 years has been reported to range between 2% and 40% with 2-dimensional and 3-dimensional conformal radiotherapy, [3] [4] [5] [6] [7] [8] and from 0% to 6% with IMRT. [9] [10] [11] [12] [13] [14] The purpose of the current study was to report the incidence of ORN of the mandible among patients with OPC treated at the study institution with IMRT, and to characterize factors associated with this late RT-related toxicity.
MATERIALS AND METHODS
After approval from the institutional research ethics board, we conducted a retrospective cohort and nested case-control study using our prospective, point-of-care quality assurance system. Patients diagnosed with squamous cell OPC who were treated with curative-intent IMRT, with or without concomitant systemic treatment, from January 2005 to December 2014 were included. Clinical characteristics, treatment modalities, and treatment toxicities were reviewed in our prospectively recorded HN anthology. 15 Human papillomavirus (HPV) status was assessed by immunohistochemistry staining for p16.
After treatment, patients were followed up by a radiation oncologist and an ear, nose, and throat surgeon at Princess Margaret Cancer Centre every 3 months for the first 2 years, every 4 months for the third year, every 6 months for the fourth year, and annually thereafter. Follow-up imaging (computed tomography or magnetic resonance imaging of the HN) was performed routinely at 8 to 12 weeks after RT to assess treatment response. Surgery for the primary tumor site was not part of the treatment strategy in these patients. A neck dissection (ND) after the completion of RT with or without systemic therapy was performed for residual disease if agreed on by both the radiation oncologist and surgeon.
Our institutional practice requires a referral to the Princess Margaret Cancer Centre dental clinic before the initiation of RT for a comprehensive dental evaluation by a dental oncologist. Patients were recommended to continue regular dental and oral hygiene and to regular follow-up, preferably with our dental clinic or with their own dentist. Patients routinely were referred back to the dental clinic at the Princess Margaret Cancer Centre when dental extraction was recommended after RT and at the first signs of ORN.
For patients with ORN, a matched 2:1 control group of patients without ORN was constructed using a combination of variables derived from the initial analysis and clinical factors suspected a priori or from the literature to potentially be related to ORN. These factors included smoking status (former/nonsmoker vs current smoker), use of systemic treatment (no vs yes), IMRT fraction size (2 grays [Gy] vs > 2 Gy), and T classification (T1-3 vs T4). In these matched cohorts, we collected the following mandibular dosimetric parameters: maximum dose (D max ), dose to 2% (D2), volume (as a percentage and in cm 3 ) receiving 50 Gy (V50), and volume (as a percentage and in cm 3 ) receiving 60 Gy (V60), as well as the mean dose (D mean ) to each of the left and right parotid gland from our treatment planning system (Pinnacle; Philips Healthcare, Madison, Wisconsin). For this same group of patients, we reviewed all dental and medical records to retrospectively collect information regarding edentulous status, pre-RT dental extractions, dental extractions after RT, use of bisphosphonates, and cardiovascular comorbidities that may be associated with an increased risk of ORN. 10, 16 ORN was graded according to the ORN scoring system of the Princess Margaret Cancer Centre (see Supporting Information Table 1 ) as follows: grade 1 indicates loss of mucosa with exposed bone requiring antibiotic treatment or the need for sequestrectomy for a duration of 3 months; grade 2 indicates loss of mucosa with exposed bone requiring antibiotic treatment or the need for sequestrectomy for a duration of >3 months and 6 months; grade 3 indicates loss of mucosa with exposed bone requiring antibiotic treatment or the need for sequestrectomy for a duration of >6 months, the need for hyperbaric oxygen therapy (HBO), or medical management with pentoxifylline/vitamin E; grade 4 indicates loss of mucosa with exposed bone requiring antibiotic treatment or the need for sequestrectomy for a duration of >12 months, the need for surgery, or pathological bone fracture; and grade 5 indicates death from ORN.
Statistical Analysis
The primary endpoint of the study was late ORN (any grade, and grade 1-2 vs grade 3-4) after RT, defined as the time from the completion of RT to the occurrence of ORN late toxicity or the last follow-up date. Death without ORN late toxicity was considered as a competing risk factor. Patients with disease recurrence (local and regional disease recurrences and distant metastasis) were censored at the date of disease recurrence. Baseline patient characteristics were compared between the patients with and those without ORN. Differences between the 2 groups were examined by the chi-square test and Student t test for categorical variables and continuous variables, respectively. The cumulative incidence function was plotted to observe the ORN rate over time. Competing risk regression models were used for both univariable (UVA) and multivariable analysis (MVA). MVA was built using the stepwise model selection algorithm. The selected variables for the MVA were those demonstrating a trend in UVA (P < .1). Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were reported correspondingly. Two-sided P values were reported for both descriptive summary and regression analyses. The Kaplan-Meier method was used for overall survival analysis. Subgroup analyses were conducted among patients with ORN and selected matched patients without ORN (1:2 match). Patients lost to follow-up were excluded from analyses (patients who had < 2 years of follow-up after the completion of RT). Data analyses were conducted using SAS statistical software (version 9.4; SAS Institute Inc, Cary, NC) and R statistical programming software (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
A total of 1223 patients with OPC were treated with IMRT with or without concomitant systemic treatment. Of these, 27 patients (2.2%) did not have at least 2 years of follow-up after RT and were excluded from subsequent analyses. The institutional dose and fractionation schedules for IMRT most frequently prescribed and selected according to the patient's performance status and comorbidities were 70 Gy in 35 fractions of 2 Gy per fraction daily 5 days per week (699 patients; 57%); 70 Gy in 35 fractions of 2 Gy per fraction at 6 fractions per week 5 days per week (271 patients; 22%); 60 Gy in 25 fractions of 2.4 Gy per fraction daily 5 days per week (118 patients; 10%); and 64 Gy in 40 fractions of 1.6 Gy per fraction twice daily, with an interval of at least 6 hours between daily fractions 5 days per week (116 patients; 9%). Nineteen patients (2%) had a different dose prescription from the above listed schedules, ranging from 50 to 74 Gy (1.2-2.6 Gy/fraction) 5 days per week. When concomitant systemic therapy was administered, RT consisted of 70 Gy in 35 fractions of 2 Gy per fraction daily 5 days per week, with either concurrent intravenous cisplatin or concurrent intravenous cetuximab. The 3-year and 5-year overall survival rates for the entire analyzed cohort were 74% and 66%, respectively. A total of 77 patients were reported to have developed ORN of the mandible, for a crude overall rate of 6%. Six patients with local and/or regional disease recurrence before the ORN event were excluded from time-toevent analysis because we considered that the salvage treatment modality may have increased the risk of late toxicity.
Characteristics of patients with (71 patients) and without (1125 patients) ORN are detailed in Table 1 . There were statistically significant differences noted between the 2 groups: a higher mean and median number of smoking pack-years for patients with ORN (P 5 .0065), more current smokers (those patients smoking actively at the time of diagnosis) in the ORN group (P 5 .048), a higher number of patients with locally advanced primary tumors among the ORN group (P 5 .0027), and a higher rate of NDs performed among patients with ORN (P 5 .031).
ORN of grades 1, 2, 3, 4, and 5 was diagnosed in 10 patients, 14 patients, 23 patients, 24 patients, and 0 patients, respectively. ORN management was as follows: medical management (antibiotics, pentoxifylline, vitamin E, and topical chlorhexidine) in 10 patients, medical management and sequestrectomy in 20 patients, HBO in 14 patients, and surgery (mandibulectomy with fibular flap reconstruction) in 13 patients. Fourteen patients received no treatment due to patient refusal (2 patients), new metastatic disease (1 patient), patient being ineligible for HBO and surgery (1 patient), and no reason reported (10 patients).
The median follow-up was 5.1 years. The median time to the development of ORN from the end of RT was 0.9 years (range, 0.2-8.2 years). The actuarial rate of ORN of the mandible was 3% at 1 year, 5% at 3 years, and 7% at 5 years (Fig. 1) . There was no statistically significant difference with regard to the incidence of ORN noted between HPV-positive and HPV-negative patients (P 5 .117).
On UVA, smoking habits (current vs nonsmoker/ former smoker) (HR, 1.83; 95% CI, 1.14-2. Original Article is interesting to note that the tumor subsite appeared to have no impact on the likelihood of developing ORN in the cohort of patients in the current study (Table 2) . We performed subgroup analysis on cohorts of HPV-positive and HPV-negative patients. Smoking history, smoking pack-years, and T classification remained statistically significant on UVA for the HPV-positive cohort, whereas no variable was found to be statistically significant in the HPV-negative population. For the patients who were HPV positive, only smoking history maintained statistical significance on MVA.
To investigate additional variables that may contribute to the development of ORN, we next performed a detailed analysis of matched cohorts of patients with ORN (71 patients) versus controls without ORN (142 patients). Specifically, we analyzed the presence of cardiovascular comorbidities, the use of bisphosphonates, pre-RT and post-RT dental extractions, edentulous status, patient compliance with dental follow-up, and RT regimen. Of these, the presence of cardiovascular comorbidities, the use of bisphosphonates, and pre-RT dental extractions each were found to have statistically significant associations with ORN (see Supporting Information Table 2 ).
Finally, a dose/volume analysis was performed for patients in the matched cohort who received an IMRT regimen of 2 Gy per fraction (56 of 71 patients with ORN and 105 of 142 patients without ORN), and found that there was a statistically significant difference in mandibular V50 (in cm 3 ) and V60 (in cm 3 ) (see Supporting Information Table 3 ); both UVA and MVA confirmed these 2 variables to be predicative of ORN (Table 3) . For both the case and control groups, the mandibular dose/volume parameters were significantly worse for patients classified with T4 disease (see Supporting Information Table 4) .
DISCUSSION
In the current study, we reviewed the incidence of ORN of the mandible in patients treated with IMRT for OPC. This population is anticipated to have high rates of cure, especially in patients with HPV-positive disease, and long-term survivors will be at risk of late toxicities such as ORN. After a median follow-up of 5.1 years, the crude rate of ORN of the mandible in the current study was 6%. Our actuarial rates for all grades were 3% at 1 year, 5% at 3 years, and 8% at 5 years. This is consistent with Tsai et al, who found an incidence of 6% for patients with OPC who are treated with IMRT, although their follow-up was shorter and they restricted their patient selection to patients with T1 to T2 disease. 14 Mendenhall et al reported an ORN rate of 3% requiring surgery in their cohort of patients with OPC who were treated with IMRT, 17 similar to our observed rate of grade 4 ORN (24 patients; 2%). Because our estimates of ORN rates were based on observed events and patients with insufficient follow-up were excluded, these estimates are the minimum expected rates because with additional follow-up, more ORN cases may develop.
We used the study institution's long-standing grading system (Table 1) to grade the severity of ORN. It is important to note that our grading system has been consistently applied over the study period in conjunction with our dental team. Because interventions (including sequestration, medical interventions, HBO, and surgery) were applied based on the duration and extent of ORN, these interventions in combination with clinical and radiographic information provide a consistent estimate of severity, which is the purpose of a grading schema. In other publications, a large variety of grading guidelines have been used, including the Radiation Therapy Oncology Group, 6, 11, 13, 18 the Common Terminology Criteria for Adverse Events, 9, 12, 19 Schwartz and Kagan grading, 7, 8 the grading system of Glanzmann and Graetz 3,10 the grading guidelines of Tsai et al 14 Lyons et al., 19 Notani et al.'s, 20 the National Cancer Institute Common Toxicity Criteria, 18 and the Late Effects of Normal Tissues Task Force/Subjective, Objective, Management, Analytic (LENT/SOMA) scale. 16 However, in some publications, the grading system is not mentioned. 4, 5, 17, 21 In the future, consensus guidelines for grading and reporting ORN may increase the consistency in literature and prospective trials. 22 When comparisons between different series are made, discrepancies that exist in the above mentioned grading systems must be taken into account. Our grading system for ORN is based on the duration of bone exposure and the management required, similar to the grading definitions of Glanzmann and Gratz 3 or Tsai et al. 14 However, the decision and timing of ORN-related interventions or treatments were based solely on our institutional experience and expertise. In the current study, we examined patients with OPC, a group who are routinely treated with definitive RT with or without systemic therapy at the Princess Margaret Cancer Centre. We excluded those individuals with carcinomas of the oral cavity, larynx, and hypopharynx to minimize confounding variables Abbreviations: 95% CI, 95% confidence interval; CRT, chemoradiotherapy; EGFRI, epidermal growth factor receptor inhibitor; GTV, gross (macroscopic) tumor volume; HPV, human papillomavirus; HR, hazard ratio; RT, radiotherapy. a Bold type indicates statistical significance.
introduced by surgical cancer management. Patients requiring mandibulotomies or mandibulectomies have been reported to have a higher risk of bone necrosis after RT. 10 However, we still observed that patients who had undergone ND had higher rates of ORN. Because ND would be performed only in those patients with residual/ recurrent neck disease, this may be related to the additional mandibular dose delivered due to treatment of macroscopic lymph nodes using a high RT dose. In patients with carcinomas of the larynx and hypopharynx, the dose delivered to the mandible usually is low due to increased tumor distance to this organ. Many prior publications have included all HN sites, which may result in a more heterogeneous population. [9] [10] [11] [12] [13] In the current series, the median time to the development of ORN of the mandible was 9 months (range, 2-98 months). The highest incidence of ORN is reported to occur between 6 months to 2 years after RT, although cases have been reported >10 to 15 years after receipt of RT. 3, 16, 19, 23 It is important to point out that there may be multiple types of toxicities described as ORN, which have been included in the current analysis. We did not have sufficient events to perform separate analyses on those patients who developed ORN rapidly (within 6 months to 24 months after treatment) compared with those who developed ORN much later (>5 years after treatment). In both our MVAs, current smoking status at the time of diagnosis was found to be significantly associated with ORN of the mandible, similar to other published series. 14, 20 Smoking is associated with poor oral hygiene, but may decrease oxygenation of tissues and affect the healing process of the acute damage and vascular disorders occurring throughout RT. The generation of acute mucosal wounds also can be increased by concomitant chemotherapy and altered fractionation, 24 although these variables were not found to significantly contribute to the incidence of ORN in the population in the current study.
Patients with a locally advanced primary tumor (classified as T4a and T4b) were found to have a higher risk of developing ORN. Two patients with T4 disease in the ORN cohort had preexisting bone invasion compared with none in the matched cohort without ORN. However, we found that for all patients (those with and without ORN), the mandibular dose/volume parameters were higher for patients with T4 disease. This finding is validated by recent dosimetric studies regarding the dose distribution with IMRT to the teeth-bearing regions. One study that included all patients with HN cancers found that the mandibular molar region received the highest doses among patients with tumors of the base of the tongue and tonsil; those with smaller tumors (classified as T1-T2) received lower doses to the anterior versus the posterior mandible, whereas the entire mandible was at risk of receiving higher doses in individuals with larger tumors (classified as T3-T4), with a threshold of 55 Gy for the development of ORN. 25 Another study that included only patients with tumors of the base of the tongue observed lower doses in the anterior mandible among those with smaller tumors, whereas patients with large tumors received high doses in the entire mandible, with the anterior bone receiving >60 Gy. 26 The comparison of clinical factors in our casecontrol analysis demonstrated differences in the use of bisphosphates and pre-RT dental extractions, and the presence of cardiovascular comorbidities. Post-RT dental extraction is a well-described trauma initiating ORN, 27 but at our institution post-RT dental extraction was an uncommon event. This could be explained by the careful pretreatment dental assessment that was performed, resulting in the extraction of decayed teeth before RT was administered; continued attention to oral hygiene after RT; the use of fluoride trays; and conservative dental treatment. However, patients with ORN were found to have a higher rate of pre-RT dental extraction compared with the cohort without ORN. Dental extraction before RT also can be viewed as a surrogate for worse dental hygiene, smoking, and comorbidities, which may predispose these patients toward a higher risk of ORN from inadequate healing. 7 Finally, we found that there were more patients with ORN who were receiving treatment with bisphosphonates, a medication that previously has been shown to increase the risk of mandibular necrosis. 28 RT and the above clinical and dental factors are recognized factors in impaired wound healing, which may be an additional contributing factor in the pathophysiology of ORN (hypovascularity-hypoxia). 29 With regard to RT dose, the volume of the mandible receiving >50 Gy or > 60 Gy was highly correlated with ORN. V50 and V60 previously have been described as being associated with the risk of ORN, and therefore it has been suggested to minimize the percentage of mandibular volume exposed to 50 Gy.
14 Several studies observed an increased risk of ORN in patients receiving >65 Gy to the mandible. 3, 4, 8, 11 Among those patients receiving the RT regimen of 2 Gy per fraction, only 3 of 56 patients with ORN and 7 of 105 patients without ORN received <70 Gy to the mandible. In the study institution, the planning goal for mandibular D max (0.1 cm 3 ) when a part of the mandible is included in the planning target volume receiving 70 Gy is 73.5 Gy; when there is no overlap of the planning target volume of 70 Gy and the mandible, the planning goal D max is 70 Gy. The target dose for the parotid glands is D mean < 26 Gy. This constraint was achieved in only 18% and 15% of the patients, respectively, among those patients with and without ORN. Xerostomia and its impact on dental decay and post-RT dental extraction can be reduced and prevented by parotid-sparing IMRT. 30, 31 The presence of patients treated with bisphosphonates complicates this dosimetric analysis because there may be an overlap between bisphosphonate-induced mandibular necrosis and ORN. We opted to include patients treated with bisphosphonates because some patients with OPC will receive treatment with bisphosphonates during clinical practice.
Although the current study is retrospective in nature, its data are derived from a very robust prospective database. In addition, the patients in the current study were treated under a universal health care system that helps to ensure that patients have consistent long-term follow-up to monitor for late toxicities such as ORN. We believe the data from the current study add to the modest quantity and quality of data concerning ORN in the IMRT era, particularly for patients with OPC. With the increasing incidence of HPV-positive OPC, and its excellent prognosis, the focus of future research should be on reducing the late treatment-related toxicity burden on long-term survivors. With the ongoing deintensification trials for HPV-positive patients with OPC, the de-escalation of the RT dose hopefully will reduce the rate of bone damage.
Conclusions
Smokers, patients with large tumors, and patients undergoing pre-RT dental extractions represent the OPC population that is most at risk of developing ORN of the mandible after undergoing curative IMRT with or without systemic treatment. IMRT optimization minimizing V50 (in cm 3 ) and V60 (in cm 3 ) should be considered in the planning process. Smoking cessation interventions need to be integrated in oncological patient care.
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